Loading…

Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis

HFE-related hereditary haemochromatosis (HH) is a common autosomal recessive disorder with clinical manifestations ranging from asymptomatic disease to possible life-threatening complications. Cirrhosis, hepatocellular carcinoma, diabetes mellitus or osteoporosis can develop in HH patients not treat...

Full description

Saved in:
Bibliographic Details
Published in:BMC health services research 2016-10, Vol.16 (1), p.573-573, Article 573
Main Authors: Vanclooster, Annick, Wollersheim, Hub, Vanhaecht, Kris, Swinkels, Dorine, Aertgeerts, Bert, Cassiman, David
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13
cites cdi_FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13
container_end_page 573
container_issue 1
container_start_page 573
container_title BMC health services research
container_volume 16
creator Vanclooster, Annick
Wollersheim, Hub
Vanhaecht, Kris
Swinkels, Dorine
Aertgeerts, Bert
Cassiman, David
description HFE-related hereditary haemochromatosis (HH) is a common autosomal recessive disorder with clinical manifestations ranging from asymptomatic disease to possible life-threatening complications. Cirrhosis, hepatocellular carcinoma, diabetes mellitus or osteoporosis can develop in HH patients not treated or monitored optimally. The purpose of this study was to develop key-interventions (KI's) to measure and improve the quality of care delivered to patients diagnosed with HH. A RAND-Modified Delphi method was used to develop KI's. In the first round of a scoring form to prioritize the recommendations extracted from evidence-based guidelines was circulated between experts. The results of this survey were discussed in a consensus meeting, followed by a final appraisal of the selected recommendations. This resulted in a list of measurable KI's. Initially, 41 key recommendations on screening, diagnosis and treatment/management were extracted from three existing guidelines on HH (European Association for the Study of the Liver, American Association for the Study of Liver Diseases and Dutch guideline on HH). Finally, a core set of 24 recommendations resulted in 15 KI's. This manuscript presents the results of the process to develop KI's to measure and improve the quality of care for patients with HH.
doi_str_mv 10.1186/s12913-016-1835-2
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5062877</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A466442270</galeid><sourcerecordid>A466442270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13</originalsourceid><addsrcrecordid>eNptUstu1DAUtRCIloEPYIMssWHj4tc4yQapqlqKqMQG1pbj3ExcJfZgJ1N1yZ9zp1NKi5AXftxzju_jEPJW8BMhavOxCNkIxbgwTNRqzeQzcix0JZlpjHr-6HxEXpVyzbmoalm9JEeyqpQS6_qY_PoKtyzEGfIO4hxSLLSDHHbQ0T6nic5DBqCwCx1ED7R1BSObBa9jiFBonzKdXHQbmJBPXUReGsd0w5YtTT3dujlgoNCbMA_08uKcDg6m5AcUd3MqobwmL3o3Fnhzv6_Ij4vz72eX7Orb5y9np1fM60bPDIwE0xrldWuaVtaqAfCd9s5zhyU2jWtxYT-8cr6Vhtd102kB0gG0GoRakU8H3e3STtB5zCq70W5zmFy-tckF-zQSw2A3aWfX3MgaG7YiH-4Fcvq5QJntFIqHcXQR0lLsfgSaN1Lsoe__gV6nJUcs7w7FlcRZ_EVt3Ag2xD7hv34vak-1MVpLWXFEnfwHhauDKfgUoQ_4_oQgDgSfUykZ-ocaBbd739iDbyz65i4dK5Hz7nFzHhh_jKJ-A4t4wHI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835032001</pqid></control><display><type>article</type><title>Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>ABI/INFORM Global</source><creator>Vanclooster, Annick ; Wollersheim, Hub ; Vanhaecht, Kris ; Swinkels, Dorine ; Aertgeerts, Bert ; Cassiman, David</creator><creatorcontrib>Vanclooster, Annick ; Wollersheim, Hub ; Vanhaecht, Kris ; Swinkels, Dorine ; Aertgeerts, Bert ; Cassiman, David ; Haemochromatosis working group ; on behalf of the Haemochromatosis working group</creatorcontrib><description>HFE-related hereditary haemochromatosis (HH) is a common autosomal recessive disorder with clinical manifestations ranging from asymptomatic disease to possible life-threatening complications. Cirrhosis, hepatocellular carcinoma, diabetes mellitus or osteoporosis can develop in HH patients not treated or monitored optimally. The purpose of this study was to develop key-interventions (KI's) to measure and improve the quality of care delivered to patients diagnosed with HH. A RAND-Modified Delphi method was used to develop KI's. In the first round of a scoring form to prioritize the recommendations extracted from evidence-based guidelines was circulated between experts. The results of this survey were discussed in a consensus meeting, followed by a final appraisal of the selected recommendations. This resulted in a list of measurable KI's. Initially, 41 key recommendations on screening, diagnosis and treatment/management were extracted from three existing guidelines on HH (European Association for the Study of the Liver, American Association for the Study of Liver Diseases and Dutch guideline on HH). Finally, a core set of 24 recommendations resulted in 15 KI's. This manuscript presents the results of the process to develop KI's to measure and improve the quality of care for patients with HH.</description><identifier>ISSN: 1472-6963</identifier><identifier>EISSN: 1472-6963</identifier><identifier>DOI: 10.1186/s12913-016-1835-2</identifier><identifier>PMID: 27733158</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Care and treatment ; Chronic obstructive pulmonary disease ; Clinical trials ; Consensus ; Continuity of Patient Care ; Delphi method ; Delphi Technique ; Diabetes ; Disease ; Evidence-Based Practice ; Gastroenterology ; Genetic Diseases, Inborn ; Guidelines as Topic ; Hemochromatosis ; Humans ; Liver cancer ; Liver cirrhosis ; Liver Diseases ; Male ; Medical care ; Osteoporosis ; Patient care planning ; Practice guidelines (Medicine) ; Primary care ; Quality Improvement ; Quality management ; Quality of Health Care ; Risk factors</subject><ispartof>BMC health services research, 2016-10, Vol.16 (1), p.573-573, Article 573</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2016</rights><rights>The Author(s). 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13</citedby><cites>FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062877/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1835032001?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11688,25753,27924,27925,36060,36061,37012,37013,44363,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27733158$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vanclooster, Annick</creatorcontrib><creatorcontrib>Wollersheim, Hub</creatorcontrib><creatorcontrib>Vanhaecht, Kris</creatorcontrib><creatorcontrib>Swinkels, Dorine</creatorcontrib><creatorcontrib>Aertgeerts, Bert</creatorcontrib><creatorcontrib>Cassiman, David</creatorcontrib><creatorcontrib>Haemochromatosis working group</creatorcontrib><creatorcontrib>on behalf of the Haemochromatosis working group</creatorcontrib><title>Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis</title><title>BMC health services research</title><addtitle>BMC Health Serv Res</addtitle><description>HFE-related hereditary haemochromatosis (HH) is a common autosomal recessive disorder with clinical manifestations ranging from asymptomatic disease to possible life-threatening complications. Cirrhosis, hepatocellular carcinoma, diabetes mellitus or osteoporosis can develop in HH patients not treated or monitored optimally. The purpose of this study was to develop key-interventions (KI's) to measure and improve the quality of care delivered to patients diagnosed with HH. A RAND-Modified Delphi method was used to develop KI's. In the first round of a scoring form to prioritize the recommendations extracted from evidence-based guidelines was circulated between experts. The results of this survey were discussed in a consensus meeting, followed by a final appraisal of the selected recommendations. This resulted in a list of measurable KI's. Initially, 41 key recommendations on screening, diagnosis and treatment/management were extracted from three existing guidelines on HH (European Association for the Study of the Liver, American Association for the Study of Liver Diseases and Dutch guideline on HH). Finally, a core set of 24 recommendations resulted in 15 KI's. This manuscript presents the results of the process to develop KI's to measure and improve the quality of care for patients with HH.</description><subject>Analysis</subject><subject>Care and treatment</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Clinical trials</subject><subject>Consensus</subject><subject>Continuity of Patient Care</subject><subject>Delphi method</subject><subject>Delphi Technique</subject><subject>Diabetes</subject><subject>Disease</subject><subject>Evidence-Based Practice</subject><subject>Gastroenterology</subject><subject>Genetic Diseases, Inborn</subject><subject>Guidelines as Topic</subject><subject>Hemochromatosis</subject><subject>Humans</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver Diseases</subject><subject>Male</subject><subject>Medical care</subject><subject>Osteoporosis</subject><subject>Patient care planning</subject><subject>Practice guidelines (Medicine)</subject><subject>Primary care</subject><subject>Quality Improvement</subject><subject>Quality management</subject><subject>Quality of Health Care</subject><subject>Risk factors</subject><issn>1472-6963</issn><issn>1472-6963</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>M0C</sourceid><sourceid>PIMPY</sourceid><recordid>eNptUstu1DAUtRCIloEPYIMssWHj4tc4yQapqlqKqMQG1pbj3ExcJfZgJ1N1yZ9zp1NKi5AXftxzju_jEPJW8BMhavOxCNkIxbgwTNRqzeQzcix0JZlpjHr-6HxEXpVyzbmoalm9JEeyqpQS6_qY_PoKtyzEGfIO4hxSLLSDHHbQ0T6nic5DBqCwCx1ED7R1BSObBa9jiFBonzKdXHQbmJBPXUReGsd0w5YtTT3dujlgoNCbMA_08uKcDg6m5AcUd3MqobwmL3o3Fnhzv6_Ij4vz72eX7Orb5y9np1fM60bPDIwE0xrldWuaVtaqAfCd9s5zhyU2jWtxYT-8cr6Vhtd102kB0gG0GoRakU8H3e3STtB5zCq70W5zmFy-tckF-zQSw2A3aWfX3MgaG7YiH-4Fcvq5QJntFIqHcXQR0lLsfgSaN1Lsoe__gV6nJUcs7w7FlcRZ_EVt3Ag2xD7hv34vak-1MVpLWXFEnfwHhauDKfgUoQ_4_oQgDgSfUykZ-ocaBbd739iDbyz65i4dK5Hz7nFzHhh_jKJ-A4t4wHI</recordid><startdate>20161013</startdate><enddate>20161013</enddate><creator>Vanclooster, Annick</creator><creator>Wollersheim, Hub</creator><creator>Vanhaecht, Kris</creator><creator>Swinkels, Dorine</creator><creator>Aertgeerts, Bert</creator><creator>Cassiman, David</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161013</creationdate><title>Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis</title><author>Vanclooster, Annick ; Wollersheim, Hub ; Vanhaecht, Kris ; Swinkels, Dorine ; Aertgeerts, Bert ; Cassiman, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Analysis</topic><topic>Care and treatment</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Clinical trials</topic><topic>Consensus</topic><topic>Continuity of Patient Care</topic><topic>Delphi method</topic><topic>Delphi Technique</topic><topic>Diabetes</topic><topic>Disease</topic><topic>Evidence-Based Practice</topic><topic>Gastroenterology</topic><topic>Genetic Diseases, Inborn</topic><topic>Guidelines as Topic</topic><topic>Hemochromatosis</topic><topic>Humans</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver Diseases</topic><topic>Male</topic><topic>Medical care</topic><topic>Osteoporosis</topic><topic>Patient care planning</topic><topic>Practice guidelines (Medicine)</topic><topic>Primary care</topic><topic>Quality Improvement</topic><topic>Quality management</topic><topic>Quality of Health Care</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vanclooster, Annick</creatorcontrib><creatorcontrib>Wollersheim, Hub</creatorcontrib><creatorcontrib>Vanhaecht, Kris</creatorcontrib><creatorcontrib>Swinkels, Dorine</creatorcontrib><creatorcontrib>Aertgeerts, Bert</creatorcontrib><creatorcontrib>Cassiman, David</creatorcontrib><creatorcontrib>Haemochromatosis working group</creatorcontrib><creatorcontrib>on behalf of the Haemochromatosis working group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC health services research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vanclooster, Annick</au><au>Wollersheim, Hub</au><au>Vanhaecht, Kris</au><au>Swinkels, Dorine</au><au>Aertgeerts, Bert</au><au>Cassiman, David</au><aucorp>Haemochromatosis working group</aucorp><aucorp>on behalf of the Haemochromatosis working group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis</atitle><jtitle>BMC health services research</jtitle><addtitle>BMC Health Serv Res</addtitle><date>2016-10-13</date><risdate>2016</risdate><volume>16</volume><issue>1</issue><spage>573</spage><epage>573</epage><pages>573-573</pages><artnum>573</artnum><issn>1472-6963</issn><eissn>1472-6963</eissn><abstract>HFE-related hereditary haemochromatosis (HH) is a common autosomal recessive disorder with clinical manifestations ranging from asymptomatic disease to possible life-threatening complications. Cirrhosis, hepatocellular carcinoma, diabetes mellitus or osteoporosis can develop in HH patients not treated or monitored optimally. The purpose of this study was to develop key-interventions (KI's) to measure and improve the quality of care delivered to patients diagnosed with HH. A RAND-Modified Delphi method was used to develop KI's. In the first round of a scoring form to prioritize the recommendations extracted from evidence-based guidelines was circulated between experts. The results of this survey were discussed in a consensus meeting, followed by a final appraisal of the selected recommendations. This resulted in a list of measurable KI's. Initially, 41 key recommendations on screening, diagnosis and treatment/management were extracted from three existing guidelines on HH (European Association for the Study of the Liver, American Association for the Study of Liver Diseases and Dutch guideline on HH). Finally, a core set of 24 recommendations resulted in 15 KI's. This manuscript presents the results of the process to develop KI's to measure and improve the quality of care for patients with HH.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27733158</pmid><doi>10.1186/s12913-016-1835-2</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1472-6963
ispartof BMC health services research, 2016-10, Vol.16 (1), p.573-573, Article 573
issn 1472-6963
1472-6963
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5062877
source Open Access: PubMed Central; Publicly Available Content Database; ABI/INFORM Global
subjects Analysis
Care and treatment
Chronic obstructive pulmonary disease
Clinical trials
Consensus
Continuity of Patient Care
Delphi method
Delphi Technique
Diabetes
Disease
Evidence-Based Practice
Gastroenterology
Genetic Diseases, Inborn
Guidelines as Topic
Hemochromatosis
Humans
Liver cancer
Liver cirrhosis
Liver Diseases
Male
Medical care
Osteoporosis
Patient care planning
Practice guidelines (Medicine)
Primary care
Quality Improvement
Quality management
Quality of Health Care
Risk factors
title Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A45%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Key-interventions%20derived%20from%20three%20evidence%20based%20guidelines%20for%20management%20and%20follow-up%20of%20patients%20with%20HFE%20haemochromatosis&rft.jtitle=BMC%20health%20services%20research&rft.au=Vanclooster,%20Annick&rft.aucorp=Haemochromatosis%20working%20group&rft.date=2016-10-13&rft.volume=16&rft.issue=1&rft.spage=573&rft.epage=573&rft.pages=573-573&rft.artnum=573&rft.issn=1472-6963&rft.eissn=1472-6963&rft_id=info:doi/10.1186/s12913-016-1835-2&rft_dat=%3Cgale_pubme%3EA466442270%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c494t-e62e6b63c4b69b2839eecd4cac0a69699ababa291c3acb260889d41e2aeeb4e13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1835032001&rft_id=info:pmid/27733158&rft_galeid=A466442270&rfr_iscdi=true